Core Viewpoint - The collaboration between Kexing Pharmaceutical and Dongyao Pharmaceutical has led to the approval of a biosimilar product, Bevacizumab injection, by the Nigerian Food and Drug Administration, marking a significant advancement in the company's strategy in the African pharmaceutical market [1] Group 1 - The approved Bevacizumab injection is indicated for the treatment of metastatic colorectal cancer, advanced or metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer [1] - The approval signifies an important step for the company in establishing its presence in the core pharmaceutical market of Africa [1]

Group 1 - Weijie Chuangxin plans to reduce its shareholding by up to 3%, amounting to no more than 12.91 million shares, due to personal funding needs [1] - Lier Chemical's major shareholder intends to reduce its stake by up to 3%, equivalent to no more than 24.01 million shares, for investment returns [1] - Helin Micro-Nano's controlling shareholder plans to reduce its shareholding by up to 1.5%, which is no more than 1.75 million shares, due to personal funding needs [2] Group 2 - Yifan Pharmaceutical received drug registration certificates for two products, indicating a focus on oncology and leukemia treatments [3] - *ST Jinbi is planning a change in control, leading to a temporary suspension of its stock trading [4] - Kexing Pharmaceutical's shareholder plans to reduce its stake by up to 3%, amounting to no more than 5.90 million shares, to optimize the equity structure [7] Group 3 - Li New Energy plans to invest approximately 1.25 billion yuan in three independent energy storage projects [7] - Kingsoft Office intends to acquire the remaining 31.98% stake in its subsidiary for 254 million yuan, aiming for full ownership [8] - Northeast Pharmaceutical received a CEP certificate from the European Medicines Agency for an antibiotic raw material, enhancing its product credibility [9] Group 4 - Tai'er Co. announced the lifting of a detention order on its controlling shareholder, changing it to a notice of supervision [10] - Runjian Co. won a bid for a solar power project worth approximately 83.92 million yuan, highlighting its role in the energy sector [11] - Jiuan Medical plans to register and issue medium-term notes and short-term financing bonds, with a total scale of up to 35 billion yuan and 5 billion yuan respectively [12] Group 5 - Wanma Co.'s chairman resigned due to work adjustments, but will remain as a board member [13] - Changhua Chemical plans to transfer 1% of its shares through an inquiry transfer method due to personal funding needs [14] - Jinkai Biotechnology's two shareholders plan to reduce their combined stake by up to 4%, totaling 481.6 thousand shares [15] Group 6 - Aeston plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [16] - Maiwei Biotechnology's chairman proposed a share buyback plan with a total amount between 25 million and 50 million yuan [17] - Montai High-tech's specific shareholders and executives plan to reduce their stake by up to 3.03%, citing personal funding needs [18] Group 7 - *ST Dongjing's stock will resume trading after a change in control, with a new actual controller [20] - Tongdahai's major shareholders plan to reduce their combined stake by up to 3.57%, totaling 345.24 thousand shares [23]

Group 1 - The Ministry of Industry and Information Technology is promoting the development of the artificial intelligence industry and empowering new industrialization, focusing on the layout of general large models and industry-specific large models, emphasizing hardware and software adaptation, and accelerating the establishment of high-quality industry data sets to enhance the intelligence level of key product equipment [1] - The Hong Kong Securities and Futures Commission is considering introducing virtual asset derivatives trading for professional investors, encouraging local and international companies to explore innovations and applications of virtual asset technology [1] - The National Energy Administration is organizing the first batch of pilot work for the construction of a new power system, coordinating regional stock and incremental data center green electricity demand and new energy resource conditions, and collaboratively planning the layout of computing power and electricity projects [1] Group 2 - The Ministry of Finance and the Ministry of Housing and Urban-Rural Development are conducting the 2025 annual evaluation for central financial support for urban renewal actions, planning to support 20 cities including Beijing and Tianjin in implementing urban renewal actions [1] - Kingsoft Office continues to appoint Lei Jun as the honorary chairman of the company [1] - Sinovac Biotech's controlling shareholder, Koyi Medicine, plans to reduce its holdings by no more than 3% of the company's shares [1] - Zhongheng Design has reported that the revenue from its "low-altitude economy" and "commercial aerospace" related project designs is relatively small [1] - Lehui International has indicated that its fresh beer business accounts for a small proportion and is still in a loss stage [1] - A portion of the company's directors and supervisors at Aoheng Co., Ltd. reduced their holdings by 153,000 shares during the period of abnormal stock trading according to the reduction plan [1] - Wantai Biological's application for marketing authorization of its nine-valent HPV vaccine has been approved [1]

证券代码：688136 证券简称：科兴制药 公告编号：2025-032 科兴生物制药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，深圳科益医药控股有限公司（以下简称"科益医药"） 直接持有科兴生物制药股份有限公司（以下简称"公司"）131,778,347 股，占 公司总股本的比例为 66.01%。科益医药直接持有的股份为其在公司首次公开发 行前取得的股份，上述股份均已上市流通。 减持计划的主要内容 科益医药本次拟通过集中竞价或大宗交易方式减持所持有的公司股份为不 超过 5,989,200 股，即不超过公司目前股份总数的 3.00%。本次减持计划自公告 披露之日起 15 个交易日后的 3 个月内（根据中国证券监督管理委员会及上海证 券交易所规定禁止减持的期间除外）进行。若减持计划实施期间公司发生送股、 资本公积金转增股本、配股等股份变动事项，将对拟减持股份数量和比例进行相 应调整。 | 股东名称 | 深圳科益医药控股有限 ...

科兴制药：股东科益医药拟通过集中竞价或大宗交易方式减持不超过598.92万股，即不超过公司目前股 份总数的3.00%。 ...

重要新闻 1. 国务院：政府部门应当科学合理确定政务数据共享属性，不得通过擅自增设条件等方式阻碍、影响政 务数据共享 李强签署国务院令，公布《政务数据共享条例》。条例提到，政府部门应当科学合理确定政务数据共享 属性，不得通过擅自增设条件等方式阻碍、影响政务数据共享。对属于有条件共享类的政务数据，政府 部门应当在政务数据目录中列明共享范围、使用用途等共享使用条件。对属于不予共享类的政务数据， 政府部门应当在政务数据目录中列明理由，并明确相应的法律、行政法规以及国务院决定依据。（新华 社） 2. 商务部等五部门组织开展2025年新能源汽车下乡活动，特斯拉Model 3、Model Y车型在列 工业和信息化部、国家发展改革委、农业农村部、商务部、国家能源局组织开展2025年新能源汽车下乡 活动。选取一批新能源汽车推广比例不高、市场潜力较大的典型县域城市，举行若干场专场活动；以此 为中心辐射周边乡镇，结合地区特点开展若干场特色活动。与县域充换电设施补短板试点、智能网联汽 车"车路云一体化"试点等工作形成协同效应，推动优质资源向乡村地区倾斜。其中，特斯拉Model 3、 Model Y车型在列。 3. 商务部：希望欧方 ...

Core Viewpoint - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors regarding recent developments and their potential impacts on company performance. Company Announcements - Shuyou Shen's application for conditional listing of STSP-0601 has been accepted by the National Medical Products Administration, aimed at treating bleeding in adult patients with hemophilia A or B, but its impact on current performance is uncertain [3] - Debang Co. has clarified that it has not yet applied autonomous driving logistics vehicles, and this concept will not affect its performance [4] - Hu Xianfu has been elected as the chairman of China Shipbuilding, with a term until the board's term ends [7] - Baili Electric reported that its involvement in controlled nuclear fusion projects has minimal revenue impact, accounting for less than 1% of total revenue in 2024 [8] - Wanrun Co.'s chairman Huang Yiwu has resigned due to work adjustments, and he will not hold any positions in the company post-resignation [9] - Kexing Pharmaceutical announced that its innovative drug projects are still in the preclinical stage, highlighting the high risks and uncertainties involved in drug development [10] Performance Metrics - Sairisi reported that the cumulative sales of the Wanjie M9 reached 50,500 units from January to May, a year-on-year increase of 19.46% [11] - Guangzhou Port expects a 4.3% year-on-year increase in container throughput for May, with a total of 2.309 million TEUs [12] Shareholding Changes - Guokang Biochemical announced that major shareholders plan to reduce their holdings by up to 6% of the company's shares [13] - Far East Co. plans to reduce its holdings by up to 2.30% due to funding needs [14] Share Buybacks - Goodway plans to repurchase shares worth between 100 million and 150 million yuan, with a maximum price of 53 yuan per share [15] - Industrial Fulian has repurchased 7,697,400 shares, using a total of approximately 147 million yuan [16][17] Strategic Partnerships - Siwei Tuxin signed a strategic cooperation framework agreement with Alibaba Cloud to enhance its automotive intelligence strategy over the next five years [18] - Del Co. plans to invest approximately 300 million yuan in new lithium battery pilot and industrialization projects [19]

Mergers and Acquisitions - Cixing Co., Ltd. plans to acquire 75% of Shenyang Shunyi Technology Co., Ltd. through a combination of issuing shares and cash payments, while also raising supporting funds from no more than 35 qualified investors [1] - United Optoelectronics intends to purchase 100% of Changyi Optoelectronics from 12 shareholders via share issuance and will also raise supporting funds [2] - Inte Group's subsidiary, Inte Pharmaceutical, successfully acquired 100% equity of Zhejiang Huadong Pharmaceutical Group Co., Ltd. for 369 million yuan and signed a transaction contract with the transferor [3] Shareholding Changes - Guokang Biochemical announced that shareholders plan to collectively reduce their holdings by no more than 6% of the company's total shares, with specific plans from two major shareholders to reduce by 3% each [4] - Ruilian New Materials reported that a major shareholder, Guofu Yongyu, plans to reduce its holdings by up to 3.33%, equivalent to 573,110 shares [5] - Hongxin Technology disclosed that two major shareholders, Baiqiang and Taizhou Qixin, plan to reduce their holdings by 2.62% and 2.12% respectively [6] Risk Matters - Sinovac Biotech highlighted the high-tech, high-risk, and high-value characteristics of its innovative drugs, emphasizing the uncertainties involved in the research and approval processes [7] - Zhongheng Design noted that the revenue from its low-altitude economy and commercial aerospace projects is minimal compared to its consolidated financial statements, despite winning several contracts in these sectors [8] Restructuring - *ST Xinyan announced that it received a notice from a creditor applying for the company's restructuring and pre-restructuring procedures [10]

证券代码：688136 证券简称：科兴制药 公告编号：2025-030 科兴生物制药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"）股票连续三个交易日 内（2025 年 5 月 29 日、5 月 30 日、6 月 3 日）收盘价格涨幅偏离值累计超过 30%， 属于股票交易异常波动。 经公司自查，并向公司控股股东、实际控制人进行书面询证，截至本公 告披露日，确认不存在关于公司的应披露而未披露的重大事项，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 二、公司关注并核实的相关情况 根据上海证券交易所相关规定，公司对相关问题进行了必要核实。现说明如 下： （一）生产经营情况 经自查，公司目前日常经营情况正常，未发生重大变化，所处的行业政策未 发生重大调整。 （二）重大事项情况 经公司自查，并向公司控股股东、实际控制人进行书面询证，截至目前，不 存在影响上市公司股票交易异常波动的重大事项，不存在其他应披露而未披露的 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/19 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 3 月 3 | 17 | 日~2026 | 年 | 月 | 16 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 530,353股 | | | | | | | 累计已回购股数占总股本比例 | 0.27% | | | | | | | 累计已回购金额 | 1,735.06万元 | | | | | | | 实际回购价格区间 | 23.14元/股~35.45元/股 | | | | | | 一、回购股份的基本情况 科兴生物制药股份有限公司（以下简称" ...